Nimotuzumab Plus S1 Versus Placebo Plus S1 as Maintenance Treatment in

Status Not yet recruiting

Clinical Trial Summary

Background: Monotherapy with S-1, oral fluoropyrimidine, shows non-inferiority to gemcitabine in overall survival (OS) with good tolerability for advanced pancreatic cancer in Asian patients. It is also shown that nimotuzumab plus gemcitabine could improve OS and progression free survival (PFS) in patients with unresectable pancreatic cancer. However, it is still unknown whether nimotuzumab plus S1 would improve more to OS and PFS than single S-1. Maintenance treatment, as a new treatment pattern, has also been tried in these patients after first line treatment to improve the OS. Thus, this study is designed to compare nimotuzumab plus S1 to placebo plus S1 as maintenance treatment in patients with locally advanced or metastatic pancreatic cancer who has benefited from the first-line treatment of gemcitabine combined with nimotuzumab and S1 (complete response+partial response+stable disease).

Patients and methods: 60 patients will be enrolled,and randomized in a 1:1 ratio to group nimotuzumab plus S1 and group placebo plus S1. nimotuzumab/placebo: 400 mg/w, intravenous infusion, Infusion time ≥ 60 min, d1, once every two weeks. S1: oral, 40 mg (Body surface area<1.5 m2) or 60 mg (Body surface area>1.5 m2), d1-d14, every three weeks for a cycle. Treatment interventions will be stopped under the conditions of disease progression or intolerable toxic reaction or participants ask to quit. The primary endpoint is the time to disease progression since randomization (TTP), secondary points include OS, 3 years overall survival rate (OSR) and safety.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02945267
Study type	Interventional
Source	Chinese PLA General Hospital
Contact	Yi Hu, PhD
Phone	13911031186
Email	huyi0401@aliyun.com
Status	Not yet recruiting
Phase	Phase 4
Start date	September 2016
Completion date	December 2019

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT02495896` - Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors	Phase 1
Not yet recruiting	`NCT06026943` - Alpha Radiation Emitters Device for the Treatment of Pancreatic Cancer Emitters for the Treatment of Locally Advanced Pancreatic Cancer	N/A
Completed	`NCT01304160` - Role of Cyberknife Stereotactic Radiation Therapy (SBRT) Followed by Gemcitabine for Patients With Locally Advanced Pancreatic Cancer	Phase 1/Phase 2
Withdrawn	`NCT05251038` - Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer	Phase 1/Phase 2
Completed	`NCT03602885` - EL CENTRO: Engaging Latinos in the Center of Cancer Treatment Options	N/A
Completed	`NCT03239184` - Bioinformation Therapy for Pancreatic Cancer	Phase 2/Phase 3
Recruiting	`NCT04002479` - Alpha Radiation Emitters Device for the Treatment of Advanced Pancreatic Cancer	N/A
Recruiting	`NCT03063554` - EUS BD vs ERCP TP for Pancreatic Cancer	N/A
Completed	`NCT03250273` - A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma	Phase 2
Not yet recruiting	`NCT06099119` - Efficacy of PERT for PEI in Unresectable Pancreatic Cancer.	Phase 4
Completed	`NCT02035072` - Phase II Study of Hypofractionated Radio-chemotherapy With Gemcitabine Plus Oxaliplatin for Unresectable Nonmetastatic Locally Advanced Pancreatic Cancer.	Phase 2
Terminated	`NCT04698915` - Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer	Phase 2
Recruiting	`NCT04789486` - Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer	Phase 1/Phase 2
Active, not recruiting	`NCT03138720` - Pre-operative Treatment for Patients With Untreated Pancreatic Cancer	Phase 2
Active, not recruiting	`NCT04395469` - FAZA PET/MRI Pancreas	N/A
Recruiting	`NCT04093141` - Chemotherapy Followed by Irreversible Electroporation in Patients With Unresectable Locally Advanced Pancreatic Cancer	N/A
Not yet recruiting	`NCT06278454` - Safety and Efficacy of NRT6008 in Patients With Unresectable Locally Advanced Pancreatic Cancer (LAPC)	Phase 1
Terminated	`NCT02166190` - RFA RCT for Pancreatic or Bile Duct Cancer	N/A
Completed	`NCT02282722` - Improving Informed Consent for Palliative Chemotherapy	N/A
Recruiting	`NCT05601323` - A Study of Suizenji in Patients With Unresectable Pancreatic Cancer	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Nimotuzumab Plus S1 Versus Placebo Plus S1 as Maintenance Treatment in Patients With Unresectable Pancreatic Cancer

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms